NCT04196335已完成不适用
I Can sEe Left Atrial Appendage (ICELAA) Clinical Study
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 100
- 试验地点
- 7
- 主要终点
- Rate of Device Leak
研究概览
简要总结
The primary objective of this study is to assess the efficacy and safety of using intra-procedural intracardiac echocardiography (ICE) for WATCHMAN FLX Device implants in subjects with non-valvular atrial fibrillation to reduce the risk of stroke.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •The subject is of legal age to participate in the study per the laws of their respective geography;
- •The subject has documented paroxysmal, persistent, permanent or long-term/longstanding persistent non-valvular atrial fibrillation (i.e., the subject does not have mitral stenosis or a mechanical heart valve);the subject has not been diagnosed with rheumatic mitral valvular heart disease);
- •The subject is deemed by the treating physician to be suitable for the protocol defined pharmacologic regimens;
- •The subject has a calculated CHA2DS2-VASc score of 2 or greater;
- •The subject is able to undergo ICE examinations;The subject is able to undergo ICE(which will be used during the index procedure) and TEE (which will be performed at 45 days and may also be performed at baseline);
- •The subject is able to understand and willing to provide written informed consent to participate in the trial;
- •The subject is able and willing to return for required follow-up visits and examinations.
排除标准
- •Subjects who are currently enrolled in another investigational study or registry that would directly interfere with the current study, except when the subject is participating in a mandatory governmental registry, or a purely observational registry with no associated treatments. Each instance must be brought to the attention of the sponsor to determine eligibility, regardless of type of co-enrollment being proposed;
- •The subject requires long-term anticoagulation therapy for reasons other than AF-related stroke risk reduction, for example due to an underlying hypercoaguable state (i.e., even if the device is implanted, the subjects would not be eligible to discontinue OAC due to other medical conditions requiring chronic warfarin therapy);
- •The subject has a history of atrial septal repair or has an ASD/PFO device;
- •The subject has an implanted mechanical valve prosthesis in any position;
- •The subject currently or has had any documented history of, New York Heart Association Class IV Congestive Heart Failure;
- •The subject is of childbearing potential and is or plans to become pregnant during the time of the study (method of assessment upon study physician's discretion).
结局指标
主要结局
Rate of Device Leak
时间窗: 45 days
Rate of significant leak (\>5 mm) as assessed by TEE at 45 days' post-implant.
次要结局
未报告次要终点
研究者
研究点 (7)
Loading locations...
相似试验
已完成
3 期
Safety and Efficacy of the CryoCor™ Cardiac Cryoablation System for the Treatment of Atrial FlutterAtrial FlutterNCT00113178Boston Scientific Corporation160
已完成
不适用
The ICE WATCHMAN TrialLeft Atrial Appendage Closure With WATCHMAN Device Utilizing an Intra-procedural ICE ProbeNCT04569734Mayo Clinic101
招募中
不适用
Left Atrial Appendage Closure in Combination With Catheter AblationAtrial FibrillationNCT03788941Xinhua Hospital, Shanghai Jiao Tong University School of Medicine1,200
已完成
不适用
Study of Intra-Cardiac Echocardiography in Guiding Left Atrial Appendage Occlusion With the Watchman DeviceLeft Atrial Appendage OcclusionNCT05136417Mayo Clinic100
Unknown
3 期
Safety and Efficacy Study of LAmbre LAA Closure Device for Treating AF Patients Who Cannot Take WarfarinAtrial FibrillationNCT02029014Lifetech Scientific (Shenzhen) Co., Ltd.154